In recent years, however, several new assays and techniques have emerged that will allow drug developers to identify more selective kinase inhibitors capable of targeting a greater range of human ...

Davies et al. reported that apart from the non-ATP mimetic inhibitors rapamycin and PD184352, even the most selective kinase inhibitors affected at least one additional protein kinase 27.

In addition to the clinical successes associated with selective kinase inhibitors, other examples of genotype-associated treatment response have been observed; for example, in the case of ...